Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2 Study of Belantamab Mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma

NCT04676360 is registered in ClinicalTrials.gov with Jacob Soumerai, MD as lead sponsor.

NCT NCT04676360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2 Study of Belantamab Mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma
Lead sponsor
Jacob Soumerai, MD
Phase
Phase 2
Overall status
Terminated
Start date
July 1, 2021
Completion date
November 26, 2024
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic lymphoma kinase positive large b-cell lymphoma, refractory plasmablastic lymphoma, relapsed plasmablastic lymphoma